Biomarkers and efficacy of vaccine responses among patients treated with new MS drug

In March 2017, the US Food and Drug Administration approved ocrelizumab as the first treatment for both relapsing (RMS) and progressive forms of multiple sclerosis (MS), a genetic disease that afflicts approximately 400,000 Americans with an estimated 10,000 new cases every year. Neurologists have now looked more deeply into the impact of ocrelizumab in these patients.

from Top Health News – ScienceDaily http://bit.ly/2HVvANl
from Tumblr http://bit.ly/2HA75Sx